Literature DB >> 1282949

Endothelium-derived kinins account for the immediate response of endothelial cells to bacterial lipopolysaccharide.

I Fleming1, T Dambacher, R Busse.   

Abstract

We have recently shown that cultured endothelial cells produce kinins that can stimulate endothelial nitric oxide (NO) production in an autocrine manner. Because both the kallikrein-kinin system and the L-arginine/NO pathway have been implicated in the pathogenesis of septic shock, we investigated the possible involvement of endothelium-derived kinins in the response of cultured endothelial cells to bacterial lipopolysaccharide (LPS). In primary cultures of human umbilical vein and porcine aortic endothelial cells, LPS (0.3 to 3 micrograms/ml) induced significant concentration-dependent increases in cyclic GMP and 6-keto-PGF1 alpha, both of which were abolished in the presence of the selective bradykinin B2-receptor antagonist HOE 140 (0.1 microM). These LPS-induced increases in cyclic GMP and 6-keto-PGF1 alpha were short lived, being maximal after 5 min but were not apparent after 60 min. In parallel with these effects, LPS (30 micrograms/ml) induced a distinct, HOE 140-sensitive increase in the intracellular calcium concentration of human endothelial cells loaded with indo-1. In summary, these data suggest that the release of endothelium-derived kinin and subsequent stimulation of endothelial cells, followed by the enhanced production of NO and prostacyclin (PGI2), are implicated in the immediate hypotension induced by LPS in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282949     DOI: 10.1097/00005344-199204002-00038

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Cutaneous venous dysfunction studied in vivo in the LPS-treated rabbit: implication of NO in saphenous vein hyporeactivity.

Authors:  Christine Vayssettes-Courchay; Marta Chataigneau; Cedric Protin; Christophe Ragonnet; Tony J Verbeuren
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-02       Impact factor: 3.000

2.  Thaliporphine increases survival rate and attenuates multiple organ injury in LPS-induced endotoxaemia.

Authors:  Chin-Wei Chiao; Shoei-Sheng Lee; Chin-Chen Wu; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-15       Impact factor: 3.000

3.  Rapid nitric oxide- and prostaglandin-dependent release of calcitonin gene-related peptide (CGRP) triggered by endotoxin in rat mesenteric arterial bed.

Authors:  X Wang; Z Wu; Y Tang; R R Fiscus; C Han
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Regulation of prostaglandin production by nitric oxide; an in vivo analysis.

Authors:  D Salvemini; S L Settle; J L Masferrer; K Seibert; M G Currie; P Needleman
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

5.  Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Authors:  M Giral; D Balsa; R Ferrando; M Merlos; J Garcia-Rafanell; J Forn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Resistance to endotoxic shock in mice lacking natriuretic peptide receptor-A.

Authors:  Catherine M Panayiotou; Reshma Baliga; Raymond Stidwill; Valerie Taylor; Mervyn Singer; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

7.  Hypotension during septic shock does not correlate with plasma levels of nitric oxide metabolites in the conscious rat.

Authors:  K Klemm; D W Mercer; D Mailman; F G Moody
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

8.  Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats.

Authors:  A Ueno; H Ishida; S Oh-ishi
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Neutral endopeptidase modulation of septic shock.

Authors:  B Lu; N P Gerard; L F Kolakowski; M Bozza; D Zurakowski; O Finco; M C Carroll; C Gerard
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.